:


1. Albain KS, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group Data Base. J Clin Oncol 1990; 8:1563.

2. Albain KS, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and III non-small cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. J Clin Oncol 1995; 13:1880.

3. American Thoracic Society/European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 1997;156:320.

4. Arriagada R, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351.

5. Auperin A, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999; 341:476.

6. Dillman RO, etal. Improved survival in stage III non-small-cell lung cancer: seven year follow-up of Cancer and Leukemia Group (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210.

7. Douillard J-Y, et al. ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I?111 > non- small-cell lung cancer patients: Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol 2005; 23(16S):7013.

8. Fosselia FV, et al. Randomized phase 111 trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing regimens. J Clin Oncol 2000; 18:2354.

9. Furuse K, et al. Phase 111 study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17:2692.

10. Gandara DR, et al. Consolidation docetaxel after concurrent chemoradi- otherapy in stage 111 non-small-cell lung cancer: phase 11 Southwest Oncology Group study S9504. J Clin Oncol 2003; 21:2004

11. Johnson DH, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113:33.

12. Kelly K, Bunn PA Jr. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung 1998; 20:85.

13. Kelly K, et al. Randomized phase 111 trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non- small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210.

14. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710.

15. Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer N Engl J //2002; 346:85.

16. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non- small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899.

17. Ost D,etal. The solitary pulmonary nodule. N Engl J Med 2003; 348:2535.

18. Pieterman RM, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000; 343:254.

19. Quinn D, et al. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest 1996; 110:1474.

20. Rosell R, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330:153.

21. Schiller J H, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92.

22. Schrevens L, et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004; 9:633.

23. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379.

24. Strauss GM, et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer: Report of Cancer and Leukemia Group (CALGB) Protocol 9633. Proc ASCO 2004; Abstract 7019.

25. Turrisi AT, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265.

26. Von Pawel J, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658.

27. Walsh GL, et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 1995; 60:1563.

28. Winton T, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. N Engl J Med 2005; 352: 2589.

: